

# 15216 COMPETITIVE PROBLEMS IN THE DRUG INDUSTRY

Dr. William F. Wood  
Dr. Aldo P. Truant

3.

August 20, 1970

## 1. Specific products for Action #2 are:

- a. Biphentamine '7 $\frac{1}{2}$ ', Biphentamine '12 $\frac{1}{2}$ ',  
Biphentamine '20'.
- b. Biphentamine-T '12 $\frac{1}{2}$ ' and Biphentamine-T '20'.
- c. Ionamin '15' and Ionamin '30'.

## 2. Pending determinations that can be achieved only in conference with F & DA officials, objectives of protocols shall include the following:

### a. 'Biphentamine' --

- (1) Short term anorectic effectiveness in "exogenous obesity", as a short term (a few weeks) adjunct in a regimen of weight reduction based on caloric restriction.
- (2) Contribution of resination in terms of
  - (a) Blood levels.
  - (b) Longer duration of effect.
  - (c) Fewer adverse reactions and less "peaking" effect.

### b. 'Biphentamine-T' --

- (1) Short term anorectic effectiveness in "exogenous obesity", as a short term (a few weeks) adjunct in a regimen of weight reduction based on caloric restriction.
- (2) Contribution of resination in terms of
  - (a) Blood levels.
  - (b) Longer duration of effect.
  - (c) Fewer adverse reactions and less "peaking" effect.
  - (d) Contribution of Thioredoxin to 'Biphentamine-T'.